BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30032274)

  • 1. Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.
    Gagliano-Jucá T; Burak MF; Pencina KM; Li Z; Edwards RR; Travison TG; Basaria S
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3900-3908. PubMed ID: 30032274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
    Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
    J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.
    Gagliano-Jucá T; Pencina KM; Ganz T; Travison TG; Kantoff PW; Nguyen PL; Taplin ME; Kibel AS; Li Z; Huang G; Edwards RR; Nemeth E; Basaria S
    Am J Physiol Endocrinol Metab; 2018 Dec; 315(6):E1185-E1193. PubMed ID: 30325657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
    Ziaran S; Goncalves FM; Breza J
    World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients.
    Urushima H; Inomata-Kurashiki Y; Nishimura K; Sumi R; Shimomura I; Nonomura N; Ito T; Maeda K
    Aging Male; 2015 Jun; 18(2):72-6. PubMed ID: 25746209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.
    Braga-Basaria M; Travison TG; Taplin ME; Lin A; Dufour AB; Habtemariam D; Nguyen PL; Kibel AS; Ravi P; Bearup R; Kackley H; Kafel H; Reid K; Storer T; Simonson DC; McDonnell M; Basaria S
    PLoS One; 2023; 18(2):e0281508. PubMed ID: 36763576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
    Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
    Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
    Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S
    J Androl; 2006; 27(6):725-8. PubMed ID: 16775253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin sensitivity during combined androgen blockade for prostate cancer.
    Smith MR; Lee H; Nathan DM
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1305-8. PubMed ID: 16434464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings.
    Hoogland AI; Jim HSL; Gonzalez BD; Small BJ; Gilvary D; Breen EC; Bower JE; Fishman M; Zachariah B; Jacobsen PB
    Cancer; 2021 May; 127(9):1476-1482. PubMed ID: 33378113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
    Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
    Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.